Skip to main content
Veterinary Medicines

Panacur, 10%, Perorální suspenze

Authorised
  • Fenbendazole

Product identification

Medicine name:
Panacur, 10%, Perorální suspenze
Active substance:
  • Fenbendazole
Target species:
  • Horse
  • Cattle
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Fenbendazole
    100.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Horse
      • Meat and offal
        no withdrawal period
    • Cattle
      • Meat and offal
        12
        day
      • Milk
        5
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC13
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet Productions
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicines
Authorisation number:
  • 10/041/76-S/C
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."